Introduction
Sphingolipids (SLs) and glycosphingolipids (GSLs) are ubiquitous components of eukaryotic cell membranes [l]. These lipids are synthesized in the endoplasmic reticulum (ER) and Golgi apparatus, but reside mainly in the outer leaflet of the plasma membrane. Significant variation exists in the types and levels of SLs and GSLs between different cells, and even within the same cell at different stages of development, implying that the regulation of SL and GSL synthesis (and degradation) is cell-type-specific and is developmentally regulated.
By definition, all SLs and GSLs are composed of a sphingoid long-chain base, to which a fatty acid is attached via an amide bond at the C-2 position (yielding ceramide) and to which a variety of headgroup moieties can be attached at C-1; variation in SL and GSL structure is due to the large number of combinations of fatty acids and headgroups that can be thus attached (Figure 1 ).
Two major classes of headgroup moiety are known. The first is phosphocholine, whose attachment to ceramide yields the phosphosphingolipid sphingomyelin (SM), a major phospholipid of animal cell membranes. Alternatively, sugars (normally glucose or galactose) are attached at the C-1 position, and it is the sequential attachment of additional sugars (both neutral and acidic) that yields the large variety of neutral and acidic GSLs (i.e. the gangliosides) [2,3]. Further variation in SL and GSL structure is a result of differences in the number of carbon units and in substitutions of the sphingoid long-chain base, and in the type of fatty acid attached to the sphingoid base at C-2 ( Figure 1) . Finally, the saturation state of the 4,sdouble bond of the sphingoid base is particularly important for the biological activity of SLs and GSLs, particularly in signalling functions [4] . As a result of these variations, hundreds of individual SL and GSL structures are known, and 
Variation in SL structure
Many hundreds of SL and GSL structures exist, owing to variation in the length and type ofthe sphingoid long-chain base, in the fatty acid attached via an amide bond at C-2 of the sphingoid base, in the headgroup attached at C-I, or in the saturation state ofthe 4.5-double bond. The molecule shown is GlcCer (N-stearoylglucosylsphingosine). See the text for more details. T h e ability to manipulate the levels and types of individual SLs and GSLs, either by genetic means or by the use of specific chemical inhibitors, should provide the means of defining some of these functions.
Here we discuss some of the work performed in our laboratory during the past few years that sheds some light on the regulation of the synthesis of SLs and GSLs, and also on the roles of particular SLs and GSLs, namely SM and glucosylceramide (GlcCer), in cell function and in particular in neuronal function. Some of these studies have been reviewed in recent articles, to which the reader is referred [6, 7] .
The regulation of GSL synthesis
As mentioned above, the sequential addition of various sugars to GlcCer or to galactosylceramide can lead to hundreds of individual GSL species.
Perhaps the best-studied GSLs are the gangliosides, the sialic acid-containing GSLs, which occur at higher levels in neuronal tissues [2], where they have been suggested to have vital roles in regulating neuronal development [8] . These suggestions were based largely on observations that the levels and types of gangliosides change during neuronal development. However, many of these conclusions were based on the study of neuronal cell lines, in which the main developmental event is transformation from a non-neuronal to a neuronal cell type, or on analysis of ganglioside composition during the development of brain tissue; clearly in the latter case, the contributions of glia and neurons must be distinguished. In our laboratory, an analysis of ganglioside synthesis in well-characterized neuronal cultures that develop by a stereotypic sequence of events giving rise to well-defined axons and dendrites [9] demonstrated that despite major
SdremaI Proposed mechanisms of regulation of GSL and SM synthesis in 3T3 fibroblasts
On incubation of 3T3 fibroblasts with FBI, ceramide synthesis is inhibrted, as a consequence, levels of the downstream metabolic precursors in the pathway of GSL synthesis are also decreased After a few ( changes in neuronal morphology and functionality, most of the changes in ganglioside synthesis are restricted to the early stages of neuronal development, namely axonogenesis and rapid axon elongation [lo] . Although this study did not resolve the issue of whether the changes in ganglioside composition regulate neuronal development or are simply a result of neuronal development, and did not resolve the roles of specific gangliosides in neuronal function, it did challenge the assumption that all stages of neuronal development are accompanied by major changes inganglioside synthesis and composition.
A more serious blow to the importance of gangliosides in development were studies showing that neuronal development proceeds essentially normally in the complete absence of complex ganglioside synthesis [11, 12] . This conclusion is based on studies in knock-out mice, in which the GM2/GD2 synthase gene was disrupted. It should be stressed that these mice synthesize simple gangliosides, and perhaps these simple gangliosides are able to function in place of the more complex ones. This issue, and the roles of gangliosides in non-neuronal tissues, will presumably be resolved after the generation of a knock-out mouse in the synthesis of all simple and complex GSLs ; cloning of GlcCer synthase has been a milestone for research in this area [13] and could provide the molecular tools for generating knock-out mice in the near future. T h e cell line used for expression cloning of GlcCer synthase has already provided some important data about the roles of GlcCer in adhesion to substratum [14] . Despite being unable to define the precise roles of gangliosides or GSLs in development, it is clear that cells expend considerable effort in regulating their synthesis. For instance, although only a minor GSL, 3T3 fibroblasts strive to maintain constant levels of globotriaosylceramide (Gb,), particularly when levels of the immediate metabolic precursors of Gb, are present in limiting amounts [15,16]. Thus, when levels of metabolic precursors are low, the synthesis of constant levels of Gb, is preserved by two mechanisms (Scheme l), namely (1) up-regulation (by transcriptional regulation) of the activity of the three glycosyltransferases in the pathway of Gb, synthesis, and (2) shunting lactosylceramide to Gb, synthesis rather than to ganglioside GM, synthesis. This is only one of a number of examples suggesting that a specific GSL (in this case Gb,) has an essential, but as yet unknown, physiological function, requiring cells to regulate its synthesis carefully.
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GlcCer synthesis and neuronal growth
Studies in our laboratory have also defined a role for GlcCer (rather than the gangliosides) in neuronal development. Initially we demonstrated that the inhibition of ceramide synthesis by fumonisin B1 (FBI) [17] altered the rate of axonal growth in hippocampal neurons [18] . More recent studies demonstrated that ceramide must be metabolized to GlcCer to sustain axonal growth [19-211. These studies have been based on the use of a combination of metabolic inhibitors of SL and GSL synthesis, and of stereoisomers of short-acyl chain derivatives of ceramide, of which some are metabolized to GlcCer and some are not. In a typical experiment, hippocampal neurons are incubated with a growth factor that specifically stimulates axonal growth [i.e. basic fibroblast growth factor (bFGF) or laminin]. Co-incubation of neurons with the growth factor and with FB1 blocks the ability of the growth factor to stimulate growth. However, the inhibitory effect of FBI can be completely reversed upon addition of D-erythroceramide (which is metabolized to GlcCer), but not of L-threo-ceramide (which is not metabolized to GlcCer) [21] . On the basis of this kind of approach, we have suggested a vital role for GlcCer in axonal growth. Although we do not known why GlcCer synthesis is required for axonal growth at this stage, it seems that GlcCer needs to be supplied continually to the growing axonal membrane to sustain growth. Remarkably, supplying ceramide to the growing axonal membrane is not sufficient to maintain growth (S. A. Boldin, M . Burack, G. Banker and A. H.
Futerman, unpublished work).
Because ongoing GlcCer synthesis is required for normal and accelerated axonal growth, we have begun to study whether the activity of GlcCer synthase is itself elevated during neuronal growth. On stimulation of axonal growth by bFGF, the activity of GlcCer synthase is up-regulated by approx. 2-3-fold when measured by assays both in wivo and in wityo. Because this up-regulation is observed within a few minutes of the application of bFGF, it cannot be due to transcriptional regulation (see above), and must instead be by post-translational modification of preexisting enzyme. T h e availability of the cDNA for this enzyme [22] , as well as a gamut of antibodies directed against the enzyme [23] , will provide the molecular tools to determine the precise mechanism(s) of regulation of GlcCer synthase.
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SM turnover and neuronal development
No discussion of the functions of SLs and GSLs, however brief, is complete today without mentioning their potential roles in signal transduction. Over the past decade it has become apparent that ceramide, when produced by the regulated hydrolysis of S M (by sphingomyelinases), acts as a second messenger in a variety of signalling pathways, most notably those involving cell death induced by Fas/tumour necrosis factor receptor [24] . In hippocampal neurons, the generation of ceramide accelerates the initial stages of neuronal development by a mechanism that is independent of its metabolism to GlcCer [20] . Because SM hydrolysis is also induced by nerve growth factor (NGF) on binding to the shared p75 neurotrophin receptor (p75NTR) [25] , we examined whether N G F stimulates S M hydrolysis in the early stages of the development of hippocampal neurons. In these neurons, p75NTR is the only detectable NGF-specific receptor, and addition of N G F does indeed lead to a dose-and time-dependent increase in the hydrolysis of S M to ceramide. T h e effects of N G F cannot be mimicked by the p75NTR-binding-deficient mutant NGFtm, but can be mimicked by anti-p75NTR antibodies (raised against the extracellular domain of p75NTR), strongly supporting a role for the p75NTR-ceramide signalling pathway in mediating the effects of N G F on the growth of cultured hippocampal neurons (A. B. Brann, R. Scott, Y. Neuberger, S. A. Boldin, M . Fainzilber and A. H . Futerman, unpublished work). Thus SM degradation at the plasma membrane seems to have an essential role in regulating the early stages of neuronal development, whereas GlcCer synthesis in intracellular compartments is essential for a later stage of development, namely axonal growth.
Aberrant neuronal growth and function in GSL storage diseases
So far there are no known metabolic diseases associated with defects in SL or GSL synthesis. It is not known whether diseases exist but simply have not been discovered owing to the lack of molecular tools to identify them. However, and in complete contrast, a large number of metabolic defects are known in the pathways of SL and GSL degradation. In these diseases, one or other of the lysosomal hydrolases that degrade a particular SL or GSL is absent or defective, resulting in the accumulation of one or other SL or GSL in lysosomes. This area has been reviewed extensively (see, for example, Kolter et al., pp.409415, this volume) and is an area of active research. However, most research focuses on molecular, diagnostic or clinical aspects, with little basic research being performed to try to define why the accumulation of GSLs in lysosomes leads to cell dysfunction.
Our laboratory has recently begun to analyse the effect of accumulation of lysosomal GlcCer on neuronal function. Mutations in the human glucocerebrosidase (glucosylceramidase, GlcCerase) gene cause a decrease in GlcCerase activity and an accumulation of GlcCer, which results in Gaucher disease, the most common lysosomal storage disease [26] . As for all lysosomal storage diseases, significant clinical heterogeneity is observed in Gaucher disease : three main types are known, varying from a chronic non-neuronopathic type (type l), to infantile (type 2) and juvenile (type 3) neuronopathic types. T h e acute neuronopathic type is characterized by a severe loss of neurons in the central nervous system and an early onset of the disease [26] . A molecular explanation for the neuronal dysfunction associated with neuronopathic forms of Gaucher disease is currently lacking and no neurotoxic agent has been identified.
As mentioned above, ongoing GlcCer synthesis is required for axonal growth in hippocampal neurons, and this is presumably related to a function of GlcCer in the secretory pathway (i.e. ER, Golgi apparatus and plasma membrane). T o determine the effects of accumulation of GlcCer in the degradative (i.e. endocytic) pathway, we have performed a series of studies with condurito1-Bepoxide (CBE), an active site-directed inhibitor of lysosomal GlcCerase [27] . We have demonstrated previously that GlcCer accumulated in neurons on treatment with CBE, resulting in changes in axonal morphology [19] , although CBE had no effects on dendrite development [28] . This latter result was surprising because aberrant neurites and ectopic dendrites have been observed in animal models of a number of SL storage diseases [29] , although not in animal models of Gaucher disease [30, 31] .
Despite the lack of gross morphological changes in CBE-treated neurons, a number of unexpected changes in neuronal functionality were observed [32] . Thus increased levels of tubular ER elements, a large increase in the response of cytosolic Ca2+ concentration to glutamate, and a large increase in cytosolic Ca2+ release from the ER in response to caffeine were detected in CBE-treated cells. There was a direct relationship between these effects and GlcCer accumulation because co-incubation with CBE and FBI completely antagonized the effects of CBE. Similar effects on ER morphology and cytosolic Ca2+ stores were observed on incubation with a short-acyl chain non-hydrolysable analogue of GlcCer, C,-glucosylthioceramide. Finally, neurons with elevated GlcCer levels were much more sensitive to the toxic effects of high concentrations of glutamate than control cells ; this enhanced toxicity was blocked by preincubation with ryanodine, suggesting that cytosolic Ca2+ release from ryanodine-sensitive intracellular Ca2+ stores can induce neuronal cell death, at least in neurons with elevated GlcCer levels. This is the first time that changes in neuronal functionality have been reported in a neuronal model of Gaucher disease, and may might help to unravel the mechanisms that lead to neuronopathic forms of the disease. Moreover, these findings might have implications for understanding not only neuronal cell death in Gaucher disease but also the neurotoxic roles of glutamate in neurodegenerative conditions.
It should be emphasized that only a small number of laboratories are studying the effects of GlcCer accumulation at the cellular level; most laboratories that work on Gaucher disease (and other lysosomal storage diseases) focus on developing new diagnostic tools and/or new treatments. Thus the challenge remains of determining the relationship between the accumulation of GlcCer in lysosomes and neuronal dysfunction or cell death. The kind of approach that we are adopting should also prove useful for understanding the mechanism of neuronal dysfunction in other lysosoma1 storage diseases, and we are currently beginning a series of studies on the functionality of cultured neurons taken from the various knockout mice that are available for many of the glycolipid storage diseases.
Perspectives
In summary, results from our and other laboratories are beginning to provide a description of the functions of individual SLs and GSLs. Surprisingly, no genetic defects are known in the pathway of S L and GSL synthesis (perhaps because these defects would be lethal) but many defects are known in the catabolic pathway. During the coming few years, it should be possible to define the roles of individual SLs and GSLs, and the cellular defects that occur when these lipids accumulate in cells, by a combination of recombinant DNA technology and the use of mouse models of the SL storage diseases.
